Trials / Completed
CompletedNCT01647633
Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash
Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash on Patient-Perceived Breathing Comfort
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Drexel University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Over 20 million Americans have allergic nasal symptoms including stuffiness, sneezing and a "runny" nose. AkPharma's Calcium Glycerophosphate used as a nasal spray wash is believed to improve these symptoms without side effects common to over the counter and prescription medication. It is hypothesized that Calcium Glycerophosphate will have a perceived improvement in breathing comfort.
Detailed description
Subjects will be screened for inclusion and exclusion criteria and consented if they fit the same criteria. They will be instructed on keeping a nasal diary of symptoms "runny, itchy, congestion, sneezing, voice changes and throat clearing". They will have blood drawn for allergy testing. After a 1 week run-in, subjects will return their diary. If they still qualify based on the diary they will have baseline labs drawn and baseline breathing test (Spirometry) performed. They will also have a nasal wash and specimen collection performed. They will be instructed on use of the nasal wash. There will be three more weekly visits before study conclusion which will include diary submission, Spirometry and nasal wash and specimen collection. On the final visit blood will again be collected as well.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Calcium Glycerophosphate Nasal Spray Wash | Nasal wash two to six times per day |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-04-01
- Completion
- 2015-05-01
- First posted
- 2012-07-23
- Last updated
- 2015-05-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01647633. Inclusion in this directory is not an endorsement.